Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: The TReprostinil sodium Inhalation Used in the Management of Pulmonary arterial Hypertension (TRIUMPH) study open-label extension
Raymond L. Benza(Triangle), Lewis J. Rubin(University of California San Diego), Werner Seeger(Justus-Liebig-Universität Gießen), Victor F. Tapson(Cedars-Sinai Medical Center), Robert Voswinckel(Justus-Liebig-Universität Gießen), Vallerie V. McLaughlin(University of Michigan), Richard N. Channick(University of California, Los Angeles), Horst Olschewski(Sigmund Freud Privatuniversität Wien), Ivan M. Robbins(Vanderbilt University Medical Center)
Cited by 106
Related Papers
Clinical classification of pulmonary hypertension
|Journal of the American College of Cardiology|2004|1.9k
Inhaled Iloprost for Severe Pulmonary Hypertension
|New England Journal of Medicine|2002|1.8k
Predicting Survival in Pulmonary Arterial Hypertension
|Circulation|2010|1.5k
Risk stratification and medical therapy of pulmonary arterial hypertension
|European Respiratory Journal|2018|834
Pulmonary hypertension in chronic lung disease and hypoxia
|European Respiratory Journal|2018|777